KR20170120617A - 수포성 표피 박리증 치료를 위한 col7a1 엑손 73에 대응하는 올리고뉴클레오타이드 - Google Patents

수포성 표피 박리증 치료를 위한 col7a1 엑손 73에 대응하는 올리고뉴클레오타이드 Download PDF

Info

Publication number
KR20170120617A
KR20170120617A KR1020177025038A KR20177025038A KR20170120617A KR 20170120617 A KR20170120617 A KR 20170120617A KR 1020177025038 A KR1020177025038 A KR 1020177025038A KR 20177025038 A KR20177025038 A KR 20177025038A KR 20170120617 A KR20170120617 A KR 20170120617A
Authority
KR
South Korea
Prior art keywords
oligonucleotide
exon
mrna
aon
antisense oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020177025038A
Other languages
English (en)
Korean (ko)
Inventor
엘리사베스 마르렌 하이스마
마르코 포트만
와우터 베우머
베라 브링크스
Original Assignee
프로큐알 테라퓨틱스 Ⅱ 비.브이.
프로큐알 테라퓨틱스 Ⅱ 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로큐알 테라퓨틱스 Ⅱ 비.브이., 프로큐알 테라퓨틱스 Ⅱ 비.브이. filed Critical 프로큐알 테라퓨틱스 Ⅱ 비.브이.
Publication of KR20170120617A publication Critical patent/KR20170120617A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020177025038A 2015-03-11 2016-03-11 수포성 표피 박리증 치료를 위한 col7a1 엑손 73에 대응하는 올리고뉴클레오타이드 Abandoned KR20170120617A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1504124.7 2015-03-11
GBGB1504124.7A GB201504124D0 (en) 2015-03-11 2015-03-11 Oligonucleotides
PCT/EP2016/055360 WO2016142538A1 (en) 2015-03-11 2016-03-11 Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy

Publications (1)

Publication Number Publication Date
KR20170120617A true KR20170120617A (ko) 2017-10-31

Family

ID=52998751

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177025038A Abandoned KR20170120617A (ko) 2015-03-11 2016-03-11 수포성 표피 박리증 치료를 위한 col7a1 엑손 73에 대응하는 올리고뉴클레오타이드

Country Status (20)

Country Link
US (2) US10563198B2 (https=)
EP (2) EP3268474B1 (https=)
JP (2) JP6929783B2 (https=)
KR (1) KR20170120617A (https=)
CN (1) CN107567498B (https=)
AU (1) AU2016231067B2 (https=)
BR (1) BR112017019225A2 (https=)
CA (1) CA2978375A1 (https=)
DK (1) DK3268474T3 (https=)
EA (1) EA035732B1 (https=)
ES (1) ES2803651T3 (https=)
GB (1) GB201504124D0 (https=)
HR (1) HRP20200944T1 (https=)
HU (1) HUE050898T2 (https=)
IL (1) IL254173B (https=)
MX (2) MX384959B (https=)
PL (1) PL3268474T3 (https=)
PT (1) PT3268474T (https=)
SI (1) SI3268474T1 (https=)
WO (1) WO2016142538A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849917B2 (en) * 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
US12227743B2 (en) 2018-01-25 2025-02-18 Osaka University Pharmaceutical composition for treatment of diseases associated with upregulated periostin expression or periostin splice variant switching
GB201902735D0 (en) 2019-02-28 2019-04-17 Proqr Therapeutics Ii Bv Oligonucleotides for use in the treatment of dystrophic epidermolysis bullosa
WO2021113270A1 (en) 2019-12-02 2021-06-10 Shape Therapeutics Inc. Therapeutic editing
WO2022122900A1 (en) * 2020-12-10 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Substances and methods for treating dystrophic epidermolysis bullosa
EP4609882A1 (en) * 2022-10-12 2025-09-03 CPC Corporation Gene introduction method, gene therapy method, and tissue regeneration method
CN116555349A (zh) * 2023-01-09 2023-08-08 中吉智药(南京)生物技术有限公司 一种腺相关病毒载体及其构建方法与应用
CN118001404B (zh) * 2024-02-06 2025-02-25 四川大学华西医院 抑制C17orf67基因表达试剂在制备治疗获得性大疱表皮松解症药物中的用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
AU2808397A (en) 1996-04-26 1997-11-19 Case Western Reserve University Skin regeneration using mesenchymal stem cells
JP2002080662A (ja) 2000-09-08 2002-03-19 Jsr Corp ゴム組成物
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
CA2790034A1 (en) 2001-06-21 2003-01-03 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
WO2003053369A1 (en) 2001-12-19 2003-07-03 Alwyn Company, Inc. Allantoin-containing preparations for administration as gels and aerosols
US20040096833A1 (en) 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of FBP-interacting repressor expression
US20040092464A1 (en) 2002-11-11 2004-05-13 Isis Pharmaceuticals Inc. Modulation of mitogen-activated protein kinase kinase kinase 11 expression
DE10238298A1 (de) 2002-08-21 2004-03-04 Beiersdorf Ag Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
AU2005215213C1 (en) 2004-02-13 2011-04-28 Smith & Nephew Orthopaedics Ag Pharmaceutical composition comprising a fibrin matrix and dermal fibroblasts for the treatment of wounds
WO2005086768A2 (en) 2004-03-11 2005-09-22 Albert Einstein College Of Medicine Of Yeshiva University Enhanced production of functional proteins from defective genes
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
GB0505202D0 (en) 2005-03-14 2005-04-20 Intercytex Ltd Skin equivalent culture
KR101083047B1 (ko) 2005-12-16 2011-11-16 주식회사 엠씨티티 간엽줄기세포의 배양방법 및 간엽줄기세포를 포함하는 피부결함의 치료용 조성물
PT2161038E (pt) 2006-01-26 2014-03-10 Isis Pharmaceuticals Inc Composições e suas utilizações dirigidas à huntingtina
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
AU2007282224B2 (en) 2006-08-11 2013-08-29 Vico Therapeutics B.V. Methods and means for treating DNA repeat instability associated genetic disorders
CA2717251A1 (en) 2007-03-07 2008-09-12 Aarhus Universitet Pig model for breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex
US8077297B2 (en) 2008-06-30 2011-12-13 Nellcor Puritan Bennett Ireland Methods and systems for discriminating bands in scalograms
EP2151248A1 (en) 2008-07-30 2010-02-10 Johann Bauer Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
WO2012018257A1 (en) 2010-08-05 2012-02-09 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
EP2672977A1 (en) * 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Antisense oligonucleotides
WO2013033436A1 (en) * 2011-09-01 2013-03-07 University Of Iowa Research Foundation Oligonucleotide-based probes for detection of bacterial nucleases
WO2013052965A2 (en) * 2011-10-06 2013-04-11 Miragen Therapeutics Control of whole body energy homeostasis by microrna regulation
EP3279324B1 (en) * 2011-10-11 2021-02-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Exon skipping therapy for dystrophic epidermolysis bullosa
CA2866563A1 (en) 2012-03-07 2013-09-12 Fibrocell Technologies, Inc. Topical dermal formulations and methods of personalized treatment of skin
US20150141320A1 (en) 2012-05-16 2015-05-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
JP6571075B2 (ja) 2013-07-08 2019-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アンチセンスオリゴヌクレオチド介在性エクソンスキッピングを、それを必要とする対象の網膜において行うための方法
US10016466B2 (en) 2014-11-17 2018-07-10 Rev Pharma Corp Topical medicament for skin and mucosal injuries associated with Epidermolisis bullosa
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
US10626401B2 (en) 2015-06-15 2020-04-21 Tirmed Pharma Ab Single-stranded oligonucleotides for use in the medical treatment of skin disorders
WO2017078526A2 (en) 2015-11-05 2017-05-11 Rijksuniversiteit Groningen Antisense oligonucleotide-mediated exon skipping as systemic therapy for recessive dystrophic epidermolysis bullosa (rdeb).

Also Published As

Publication number Publication date
EA201791986A1 (ru) 2018-01-31
US10563198B2 (en) 2020-02-18
WO2016142538A1 (en) 2016-09-15
JP2018509903A (ja) 2018-04-12
PT3268474T (pt) 2020-06-17
SI3268474T1 (sl) 2020-07-31
IL254173A0 (en) 2017-10-31
AU2016231067A1 (en) 2017-10-26
HUE050898T2 (hu) 2021-01-28
EP3763816A1 (en) 2021-01-13
IL254173B (en) 2022-03-01
GB201504124D0 (en) 2015-04-22
EA035732B1 (ru) 2020-07-31
CN107567498B (zh) 2021-09-21
MX2017011599A (es) 2018-06-15
US11352626B2 (en) 2022-06-07
EP3268474A1 (en) 2018-01-17
AU2016231067B2 (en) 2022-04-21
JP2022000020A (ja) 2022-01-04
US20200399638A1 (en) 2020-12-24
ES2803651T3 (es) 2021-01-28
JP6929783B2 (ja) 2021-09-01
JP7188810B2 (ja) 2022-12-13
EP3268474B1 (en) 2020-05-27
HRP20200944T1 (hr) 2020-09-18
CN107567498A (zh) 2018-01-09
MX384959B (es) 2025-03-14
NZ736083A (en) 2021-08-27
PL3268474T3 (pl) 2020-08-24
BR112017019225A2 (pt) 2018-05-08
CA2978375A1 (en) 2016-09-15
MX2021009135A (es) 2021-09-10
DK3268474T3 (da) 2020-06-15
US20180216106A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
JP7188810B2 (ja) 表皮水疱症治療のためのｃｏｌ７ａ１エクソン７３とマッチするオリゴヌクレオチド
KR102368918B1 (ko) 레베르 선천성 흑암시 치료용 올리고뉴클레오타이드
JP7188804B2 (ja) ジストロフィー型表皮水疱症を処置するためのアンチセンスオリゴヌクレオチド
HK40044776A (en) Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy
NZ736083B2 (en) Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy
HK1242376B (en) Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy
US20220127610A1 (en) Oligonucleotides for use in the treatment of dystrophic epidermolysis bullosa
NZ737592B2 (en) Antisense oligonucleotides to treat dystrophic epidermolysis bullosa

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904